66 results
6-K
EX-99.1
IPHA
Innate Pharma
21 Mar 24
Summary of Consolidated Financial Statements and Notes
9:20am
Total current assets
Intangible assets
Property and equipment
Non-current financial assets
Other non-current assets
Deferred tax assets
Trade receivables … – Current portion
Deferred tax liabilities
Total non-current liabilities
Share capital
Share premium
Retained earnings
Other reserves
Net income (loss
6-K
EX-99.1
y5m690svqd58996
21 Mar 24
Innate Pharma reports Full Year 2023 Financial Results and Business Update
6:01am
6-K
EX-1.1
pec 62tpkxzajno03f8
6 Feb 24
Current report (foreign)
5:05pm
6-K
EX-5.1
iet x1hl7
6 Feb 24
Current report (foreign)
5:05pm
424B5
k2ov al1j48w
6 Feb 24
Prospectus supplement for primary offering
5:00pm
F-3
EX-5.1
79tf 8bb68b0w
20 Dec 23
Shelf registration (foreign)
4:45pm
F-3
foscjmn jx
20 Dec 23
Shelf registration (foreign)
4:45pm
6-K
gu2wmkb7hlu3
20 Dec 23
Current report (foreign)
4:30pm
6-K
EX-99.2
kdn2xc yny
14 Sep 23
Innate Pharma Reports First Half 2023 Financial Results and Business Update
6:27am
6-K
EX-99.1
y7mbjc5psi8vu nn3
14 Sep 23
Innate Pharma Reports First Half 2023 Financial Results and Business Update
6:27am
6-K
EX-99.1
vitjx5de
14 Sep 23
Innate Pharma S.a. 6-K
6:00am
6-K
EX-1.1
x10krbqqdtt6lg
26 Apr 23
Current report (foreign)
4:02pm
424B5
h5m1az4vbx6kf2x2
26 Apr 23
Prospectus supplement for primary offering
4:01pm
20-F/A
EX-4.9
34k5xw5vzl
20 Apr 23
Annual report (foreign) (amended)
8:47am
6-K
EX-99.1
sx3pi
15 Sep 22
Innate Pharma Reports First Half 2022 Financial Results and Business Update
6:12am